Burgdorf – Ypsomed investing in Switzerland.
For the Burgdorf-based diabetes specialist Ypsomed, the first six months of the business year have been in line with the expectations already announced. For the last time, a fall in sales to the former key customer Sanofi was recorded. It was possible to largely offset this decline through rigorous cost management, resulting in an operating profit slightly below the figure for the previous year. Over the past few years, Ypsomed has been broadening its foundations and is now looking to reap the benefits of its diversified sales base and return to the path of growth. The authorized capital increase earmarked to finance this growth strategy was approved by the shareholders in June 2012. Investment opportunities are currently being weighed up, with no decisions having been taken as yet.